Feinberg Award Won by Chinese Scientist Wang Yongjun for Stroke Research
Chinese clinical scientist Wang Yongjun was honored with the William M. Feinberg Award for Excellence in Clinical Stroke during the 2025 International Stroke Conference (ISC) in Los Angeles on Wednesday.
TroibNews 
Chinese clinical scientist Wang Yongjun was honored with the William M. Feinberg Award for Excellence in Clinical Stroke during the 2025 International Stroke Conference in Los Angeles on Wednesday, due to his substantial contributions to stroke clinical research and management.
Established by the American Stroke Association, the Feinberg Award is regarded as the highest accolade in stroke clinical medicine. This marks the first occasion in its 34-year history that an Asian scientist has received the award.
Wang serves as the president of both Beijing Tiantan Hospital and the Chinese Stroke Association. Over the past three decades, his team has generated 12 pivotal pieces of evidence that have significantly influenced clinical guidelines and practices in stroke treatment.
"It is very fortunate that our team has been a major force in providing evidence of intravenous thrombolytic therapy for ischemic stroke," Wang stated.
"Several clinical trials are still ongoing, including thrombolysis with Tenecteplase for minor ischemic strokes, basilar artery occlusion, and thrombolysis for ischemic stroke at very late time windows," he added.
His team's efforts have expanded the intravenous thrombolysis time window from 4.5 hours to 24 hours through the use of imaging and artificial intelligence technologies. This advancement allows 90 percent of acute ischemic stroke patients the opportunity to receive thrombolytic therapy, decreasing the disability rate among patients by 8.8 percent without elevating the risk of intracranial hemorrhage.
Moreover, they devised a treatment that combines aspirin and clopidogrel, effectively lowering global stroke recurrence rates from 11 percent to 6 percent. Their work has contributed to reducing the recurrence of strokes for nearly one million stroke patients in China.
Wang underscored the significance of teamwork, emphasizing that more than 2,400 hospitals in China participate in their clinical research network.
In light of China's substantial stroke burden, its scientific teams have been engaged in pioneering research aimed at addressing global challenges related to stroke prevention and treatment.
Over the past decade, medical scientists from Beijing Tiantan Hospital have conducted more than 50 national clinical studies, with 14 providing Chinese solutions for international stroke prevention and treatment.
The Feinberg Award is named in honor of the late William M. Feinberg, a distinguished stroke clinician and researcher whose work enhanced the understanding of stroke causes.
The three-day ISC, attended by around 4,000 professionals, showcases the latest innovations in stroke prevention, treatment, and rehabilitation on a global scale.
James del Carmen contributed to this report for TROIB News
Established by the American Stroke Association, the Feinberg Award is regarded as the highest accolade in stroke clinical medicine. This marks the first occasion in its 34-year history that an Asian scientist has received the award.
Wang serves as the president of both Beijing Tiantan Hospital and the Chinese Stroke Association. Over the past three decades, his team has generated 12 pivotal pieces of evidence that have significantly influenced clinical guidelines and practices in stroke treatment.
"It is very fortunate that our team has been a major force in providing evidence of intravenous thrombolytic therapy for ischemic stroke," Wang stated.
"Several clinical trials are still ongoing, including thrombolysis with Tenecteplase for minor ischemic strokes, basilar artery occlusion, and thrombolysis for ischemic stroke at very late time windows," he added.
His team's efforts have expanded the intravenous thrombolysis time window from 4.5 hours to 24 hours through the use of imaging and artificial intelligence technologies. This advancement allows 90 percent of acute ischemic stroke patients the opportunity to receive thrombolytic therapy, decreasing the disability rate among patients by 8.8 percent without elevating the risk of intracranial hemorrhage.
Moreover, they devised a treatment that combines aspirin and clopidogrel, effectively lowering global stroke recurrence rates from 11 percent to 6 percent. Their work has contributed to reducing the recurrence of strokes for nearly one million stroke patients in China.
Wang underscored the significance of teamwork, emphasizing that more than 2,400 hospitals in China participate in their clinical research network.
In light of China's substantial stroke burden, its scientific teams have been engaged in pioneering research aimed at addressing global challenges related to stroke prevention and treatment.
Over the past decade, medical scientists from Beijing Tiantan Hospital have conducted more than 50 national clinical studies, with 14 providing Chinese solutions for international stroke prevention and treatment.
The Feinberg Award is named in honor of the late William M. Feinberg, a distinguished stroke clinician and researcher whose work enhanced the understanding of stroke causes.
The three-day ISC, attended by around 4,000 professionals, showcases the latest innovations in stroke prevention, treatment, and rehabilitation on a global scale.
James del Carmen contributed to this report for TROIB News
